Cadila Healthcare informs about press release

17 Apr 2019 Evaluate

Cadila Healthcare has informed about submission of a press release titled ‘Zydus Announces Phase 3 Trial of Desidustat in Non-Dialysis Dependent Chronic Kidney Disease (CKD) Patients with Anemia’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

893.45 11.50 (1.30%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×